Immunomedics


Immunomedics is a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer.
Immunomedics was founded in July 1982 by David M. Goldenberg. Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019. Dr. Behzad Aghazadeh was named Executive Chairman of the Board of Directors after Pehl's departure.

Pipeline